Approval · Notice of Compliance 28446 · 2022
SCEMBLIX: Notice of Compliance 28446
Issued June 22, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 28446
- Date
- June 22, 2022
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
Products in this notice
Medicinal ingredients
- ASCIMINIB HYDROCHLORIDE 20 MG per TAB
- ASCIMINIB HYDROCHLORIDE 40 MG per TAB